Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Immunogenicity, Reactogenicity and Safety of a Second Booster with BNT162b2 or Full-Dose mRNA-1273: A Randomised VACCELERATE Trial in Adults ≥75 Years (EU-COVAT-1-AGED Part B)

10.2139/ssrn.4671824Source: DataRank Database

Immunogenicity, Reactogenicity and Safety of a Second Booster with BNT162b2 or Full-Dose mRNA-1273: A Randomised VACCELERATE Trial in Adults ≥75 Years (EU-COVAT-1-AGED Part B) is a research paper. On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

0 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)OA: greenTopics (27)IDs (PubMed)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (40)

Lusine Yeghiazaryan,Christoph Stephan ORCID,Kirsten Greve-Isdahl Mohn,Antonio J Carcas,Esperanza Romero Rodriguez

Live enrichment

PubMed:19910364

European Commission

Grant: 101037867

VACCELERATE - European Corona Vaccine Trial Accelerator Platform

greenLicense: CC BY NC ND

repositoryhttp://dx.doi.org/10.2139/ssrn.4671824

https://doi.org/10.2139/ssrn.4671824

https://doi.org/10.1016/j.ijid.2024.107161

https://pubmed.ncbi.nlm.nih.gov/38992789

http://hdl.handle.net/10486/720557

Fields of Study

03 medical and health sciences0303 health sciences

Keywords

MaleCOVID-19 VaccinesImmunosenescenceMedicinaImmunization, SecondaryInfectious and parasitic diseasesRC109-216Neutralizing antibodiesAntibodies, ViralImmunogenicity, VaccineHumansBooster vaccinationBNT162 VaccineAgedVariants of concernAged, 80 and overSARS-CoV-2COVID-19Advanced ageAntibodies, NeutralizingImmunoglobulin GSpike Glycoprotein, CoronavirusFemaleHuman medicine2019-nCoV Vaccine mRNA-1273

Sustainable Development Goals

SDG 3: 3. Good healthSDG 16: 16. Peace & justice

Immunogenicity, Reactogenicity and Safety of a Second Booster with BNT162b2 or Full-Dose mRNA-1273: A Randomised VACCELERATE Trial in Adults ≥75 Years (EU-COVAT-1-AGED Part B)

FAIR Checklist

Authors (40)

Funding (1 grants)

Open Access

Topics